Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V/MPA.
From the results, the investigators will compare the effect of tibolone versus E2V/MPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.
>20 years old female
Menopausal symptoms, still have a uterus, and no breast or other cancers, and no vascular-blocking disease such as stroke.
Nil.
Women with menopausal symptoms
Case-control
Prospective
Tibolone 2.5 mg
DrugTibolone 2.5 mg per day
Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
DrugEstradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Overactive bladder symptoms
Compare the effect of tibolone versus E2V/MPA on the total score of Overactive Bladder symptoms Score Total scores:0-15, the minimum values and whether lowest scores mean a better outcome
Sexual function index
Compare the effect of tibolone versus E2V/MPA on total score of the Female Sexual Function Index Total scores:4-95, the maximum values and whether higher scores mean a better outcome.
Autonomic function
Compare the effect of tibolone versus E2V/MPA on heart rate variability parameters
Arterial stiffness
Compare the effect of tibolone versus E2V/MPA on cardio-ankle vascular index
Atherosclerosis
Compare the effect of tibolone versus E2V/MPA on ankle-brachial pressure index
Click on the lead sponsor to view all of their trials.
